- Reference #:
- WL 2277
Recipient NameElizabeth Hanlon
- Rite Aid Corporation
200 Newberry Commons
Etters, PA 17319
- Issuing Office:
- Center for Drug Evaluation and Research | CDER
Dear Ms. Hanlon:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 2277. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter and corrected the data deficiencies. We have received an updated listing SPL with the correct list of active ingredients and an updated labeler code request SPL with the updated contact information. Future FDA regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and to continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Carolyn E. Becker, JD
Director, Office of Unapproved Drugs & Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research U.S. Food and Drug Administration